EBS Emergent Biosolutions Inc.

52.58
-1.54  -3%
Previous Close 54.12
Open 54.32
Price To Book 2.62
Market Cap 2,714,368,678
Shares 51,623,596
Volume 276,572
Short Ratio 7.68
Av. Daily Volume 303,719
Stock charts supplied by TradingView

NewsSee all news

  1. Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate

    GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of

  2. Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day

    GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the

  3. Emergent BioSolutions to Host 2019 Analyst and Investor Day

    GAITHERSBURG, Md., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event

  4. Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

    Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the third

  5. Emergent BioSolutions to Host 2019 Analyst & Investor Day

    GAITHERSBURG, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to commence in 2020.
FLU-IGIV
Influenza A
Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
VLA1601
Zika vaccine
Phase 2 interim analysis noted 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination - November 22, 2019.
CHIKV-VLP
Chikungunya virus

Latest News

  1. Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate

    GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of

  2. Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day

    GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the

  3. Emergent BioSolutions to Host 2019 Analyst and Investor Day

    GAITHERSBURG, Md., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event

  4. Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

    Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the third

  5. Emergent BioSolutions to Host 2019 Analyst & Investor Day

    GAITHERSBURG, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which

  6. Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

    GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company's chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was

  7. Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

    GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the

  8. Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

    GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National

  9. Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

    GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the Cantor Fitzgerald Global

  10. Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

    GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing

  11. Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

    Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weaponSupports the government's continued efforts and long-term strategy to maintain sufficient